Skip to main content
LEAP THERAPEUTICS, INC. logo

LEAP THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LPTX ISIN · US52187K2006 LEI · 549300T31SMMJ2DDLI13 US Manufacturing
Open in API
Filings indexed 584 across all filing types
Latest filing 2019-02-01 Capital/Financing Update
Country US United States of America
Listing US LPTX

About LEAP THERAPEUTICS, INC.

https://www.leaptx.com/

Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics for cancer. Its most advanced clinical candidate, DKN-01 (sirexatamab), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, being developed for patients with esophagogastric, gynecologic, and colorectal cancers. The company's pipeline also includes FL-301, a monoclonal antibody targeting Claudin18.2 for gastric and pancreatic cancer, and FL-501, a preclinical antibody targeting the growth and differentiation factor 15 (GDF-15) protein.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions that the company issued a press release announcing the pricing of a public offering of common stock and warrants. The document is short (3281 characters) and primarily serves to announce this event rather than provide detailed financial data or a full report. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. It is not an earnings release or annual report, nor is it a regulatory filing for certifications or legal matters. Therefore, the correct classification is CAP with high confidence.
2019-02-01 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) related to a securities offering by Leap Therapeutics, Inc. It includes detailed information about the offering of common stock and warrants, underwriting details, and legal disclaimers. The document is a registration and offering prospectus supplement, which is a type of capital raising disclosure. It is not a financial report, earnings release, management discussion, or any other type of report listed in the filing definitions. It clearly relates to a capital/financing update regarding the issuance of new securities and the terms of the offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a mere announcement or a regulatory filing fallback, but a substantive offering document.
2019-01-31 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 31, 2019, by Leap Therapeutics, Inc. The key content is an announcement of a proposed public offering of common stock and warrants. The document includes a press release as an exhibit but does not contain financial statements or detailed financial data itself. The length is 3235 characters, which is relatively short and consistent with an announcement rather than a full report. The nature of the filing is an update on financing activities (public offering). Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2019-01-31 English
8-K
Delisting Announcement Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated January 24, 2019, by Leap Therapeutics, Inc. The key content is under Item 3.01, which is titled 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.' The document details that the company received a notification from Nasdaq about failing to maintain the minimum market value of listed securities (MVLS) required for continued listing on The Nasdaq Global Market. It explains the compliance period and potential consequences if the company does not regain compliance. There is no financial data or report content, only an official notice regarding delisting status. According to the filing definitions and rules, this is an official notice of delisting, which fits the category 'Delisting Announcement' (DLST). The document length is about 4926 characters, which is sufficient to contain substantive content, not just a brief announcement or link. Therefore, the classification is DLST with high confidence.
2019-01-30 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates it is a short filing (3644 characters) reporting an event: the issuance of a press release about an investigator-initiated study. It does not contain financial statements or detailed financial data, nor is it an annual or quarterly report. The document is primarily an announcement of an event and includes a press release as an exhibit. Given the short length and nature of the content, it fits the category of a Regulatory Filing (RNS), which is a general regulatory announcement and a fallback category for miscellaneous filings that do not fit other specific categories.
2019-01-14 English
4
Director's Dealing
2019-01-03 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.